capecitabine has been researched along with Infections, Coronavirus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bodea, R; Mercea, V; Nemes, A; Vidra, R | 1 |
| Sun, L; Xu, Y; Yang, Y; Zhang, T | 1 |
2 other study(ies) available for capecitabine and Infections, Coronavirus
| Article | Year |
|---|---|
Challenges of pancreatic cancer chemotherapy in the COVID-19 era.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Capecitabine; Coronavirus Infections; COVID-19; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Pandemics; Pneumonia, Viral; Romania; SARS-CoV-2 | 2020 |
Impact of the COVID-19 outbreak on adjuvant chemotherapy for patients with stage II or III colon cancer: experiences from a multicentre clinical trial in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Capecitabine; Chemotherapy, Adjuvant; China; Colonic Neoplasms; Coronavirus Infections; COVID-19; Disease Outbreaks; Drugs, Chinese Herbal; Hospitals; Humans; Neoplasm Staging; Organizational Policy; Oxaliplatin; Pandemics; Patient Selection; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2; Time-to-Treatment | 2020 |